5 Cybersecurity Myths That Put Your Medical Device Clearance at Risk
Synopsis
Understanding and mitigating cybersecurity risks is paramount for medical device manufacturers seeking market clearance. This webinar debunks five common myths that can jeopardize this process. We will explore how prevalent misconceptions often lead to critical oversights in device security, potentially delaying or even preventing regulatory approval. The discussion will cover the importance of integrating robust cybersecurity practices throughout the medical device lifecycle, from design and development to post-market surveillance. Attendees will gain a clearer understanding of regulatory expectations and best practices to ensure their devices meet the stringent security requirements for clearance.
Key takeaways
- Myth 1: Cybersecurity is a post-market concern. (Fact: Cybersecurity must be integrated from the design phase, evidenced by IEC 62304 and ISO 14971)
- Myth 2: Basic security features are sufficient. (Fact: Regulators like the FDA, especially with Section 524B, expect comprehensive risk management and advanced security controls.)
- Myth 3: Compliance is purely a documentation exercise. (Fact: Demonstrable implementation of security controls, verified through testing and evidence in eSTAR submissions, is crucial.)
- Myth 4: SBOMs are optional. (Fact: Software Bill of Materials (SBOM) and Vulnerability Exploitability eXchange (VEX) are becoming critical for transparency and proactive vulnerability management.)
- Myth 5: Small manufacturers are exempt from rigorous cybersecurity requirements. (Fact: All manufacturers, regardless of size, must adhere to relevant cybersecurity standards and frameworks like AAMI TIR57 and prepare for SPDF submissions.)
Get FDA cleared without the cybersecurity headaches.
30-minute strategy session. No cost, no commitment - just answers from people who've shipped 250+ submissions.